Browsing by Author "Pardal, C"
Now showing 1 - 6 of 6
Results Per Page
Sort Options
- 0 papel do LBA na identificação de Pneumonia a Pneumocystis cariniiPublication . Pardal, C; Rosa, P; Fernandes, L; Longo, C; Sustelo, Arminda
- Cessação tabágica: alguns argumentos para motivar o fumadorPublication . Pardal, C
- Cigarros eletrónicos e indução do tabagismoPublication . Pardal, C
- Fisiologia de atletas de trampolins de alta competição portugueses ou a fibra que promove campeõesPublication . Longo, C; Costa, R; Chilumbo, A; Pardal, C; Almeida, JOs resultados desportivos excelentes a nível internacional dos atletas de trampolins levaram-nos a proceder a um estudo de modo a avaliar quais as suas características principais a nível fisiológico para o sucesso nesta modalidade. O que diferencia os atletas de elite (europeu e mundial) de trampolim dos atletas de nível distrital da mesma modalidade. Com esses objectivos estudámos 17 atletas de trampolins de alta competição (AC) e comparámo-los com 10 atletas de modalidades gímnicas mas de nível distrital (grupo de controlo). Estudámos o metabolismo aeróbico e anaeróbico (láctico e aláctico ). Realizamos para o efeito prova de esforço máxima em ciclo ergómetro com carga inicial de 1 watt/kg de peso e incrementos todos os 2 minutos. Calculámos a potência aeróbica máxima (PAM) através da fórmula proposta por VAGO. Retirámos sangue para lactatos no final do esforço (LM) e aos 3 minutos de recuperação (LR). Para avaliação do metabolismo anaeróbico aláctico utilizámos o teste de impulsão vertical e seguidamente através da fórmula de Lewis calculámos a potência anaeróbica aláctica (P Alact). Fizemos análise de variância e estudo de coeficientes parciais de correlação através de regressão linear múltipla. Os atletas de alta competição (AC) tinham idades médias de 18,7 +/- 2.54 anos e o grupo de controlo de 16,7 +/- 2.06. No AC 7 atletas eram do sexo feminino (F) e 10 do sexo masculino (M); o grupo de controlo eram 4 do sexo feminino e 6 do sexo masculino.Trampolim AC Controlo P VO2max (l) 3,2 +/- 0.62 3,07 +/- 0.66 NS PAM (W) 236,09 +/- 49.24 225,52 +/- 52.58 NS LM (mmol/l) 8,75 +/- 1.75 6,64 +/- 2.35 <0.05 LR (mmol/l) 8,32 +/- 1.72 5,83 +/- 1.89 <0.05 PAlact (W) 106,66 +/- 22.58 90,81 +/- 13.84 <0.05 Conclusão: Encontrámos diferenças com significado estatístico nos 2 componentes do metabolismo anaeróbico entre os 2 grupos estudados. Os atletas de trampolins de alta competição têm uma taxa mais elevada de metabolismo anaeróbico láctico o que certamente terá a ver com prestação desportiva de alto nível.
- Omalizumab for Severe Asthma: Beyond Allergic Asthma.Publication . Loureiro, C; Anmaral, L; Ferreira, A; Lima, R; Pardal, C; Fernandes, I; Semedo, L; Arrobas, ADifferent subsets of asthma patients may be recognized according to the exposure trigger and the frequency and severity of clinical signs and symptoms. Regarding the exposure trigger, generally asthma can be classified as allergic (or atopic) and nonallergic (or nonatopic). Allergic and nonallergic asthma are distinguished by the presence or absence of clinical allergic reaction and in vitro IgE response to specific aeroallergens. The mechanisms of allergic asthma have been extensively studied with major advances in the last two decades. Nonallergic asthma is characterized by its apparent independence from allergen exposure and sensitization and a higher degree of severity, but little is known regarding the underlying mechanisms. Clinically, allergic and nonallergic asthma are virtually indistinguishable in exacerbations, although exacerbation following allergen exposure is typical of allergic asthma. Although they both show several distinct clinical phenotypes and different biomarkers, there are no ideal biomarkers to stratify asthma phenotypes and guide therapy in clinical practice. Nevertheless, some biomarkers may be helpful to select subsets of atopic patients which might benefit from biologic agents, such as omalizumab. Patients with severe asthma, uncontrolled besides optimal treatment, notwithstanding nonatopic, may also benefit from omalizumab therapy, although currently there are no randomized double-blind placebo controlled clinical trials to support this suggestion. However, omalizumab discontinuation according to each patient's response to therapy and pharmacoeconomical analysis are questions that remain to be answered
- The Portuguese Severe Asthma Registry: Development, Features, and Data Sharing PoliciesPublication . Sá-Sousa A1, A; Fonseca, JA; Pereira, AM; Ferreira, A; Arrobas, A; Mendes, A; Drummond, M; Videira, W; Costa, T; Farinha, P; Soares, J; Rocha, P; Todo-Bom, A; Sokolova, A; Costa, A; Fernandes, B; Loureiro, C; Longo, C; Pardal, C; Costa, C, et al.The Portuguese Severe Asthma Registry (Registo de Asma Grave Portugal, RAG) was developed by an open collaborative network of asthma specialists. RAG collects data from adults and pediatric severe asthma patients that despite treatment optimization and adequate management of comorbidities require step 4/5 treatment according to GINA recommendations. In this paper, we describe the development and implementation of RAG, its features, and data sharing policies. The contents and structure of RAG were defined in a multistep consensus process. A pilot version was pretested and iteratively improved. The selection of data elements for RAG considered other severe asthma registries, aiming at characterizing the patient's clinical status whilst avoiding overloading the standard workflow of the clinical appointment. Features of RAG include automatic assessment of eligibility, easy data input, and exportable data in natural language that can be pasted directly in patients' electronic health record and security features to enable data sharing (among researchers and with other international databases) without compromising patients' confidentiality. RAG is a national web-based disease registry of severe asthma patients, available at asmagrave.pt. It allows prospective clinical data collection, promotes standardized care and collaborative clinical research, and may contribute to inform evidence-based healthcare policies for severe asthma.